Slide 1: 2026 ASCO Annual Meeting: LB2102 Phase 1 results
2026 ASCO ANNUAL MEETING Results from the Phase 1 study of LB2102, a dnTGFBR2- armored, DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC AUTHORS: Z Hao, A Chiqppori, B Creelon, R Munker, P Schwarzenberger, N Patel, S Vchorg C Davis, CWang, JZhong, L
Slide 2: Key Takeaway Points
4 Key Takeaway Points LB2102 has a favorable safety profile across 6 dose levels tested in 20 heavily pretreated subjects with relapsed/refractory SCLC or LCNEC No DLTs; CRS and ICANS are manageable Encouraging anti-tumor activity were seen at Dose Levels 2 3 (2.0-16 x 10°CAR+ T cells/kg) Objective
Slide 3: LB2102: DLL3-targeted Autologous CAR-T Cells With dnTGFBR2 Armor
4 LB2102 : DLL3-targeted Autologous CAR-T Cells With dnTGFBR2 Armor DLL3 * An inhibitory Notch ligand highly expressed on the cell surface in SCLC and other neuroendocrine tumors dnTGFBR2 * Minimal expression in normal tissues LB2102 CAR-T Cell Design H + Chimeric antigen receptor (CAR): dual single
Slide 4: LB2102 First-in-human Phase 1, Open Label, Multi-Center Study
> 4 LB2102 First-in-human Phase 1, Open Label, Multi- Center Study Part A: Dose escalation i3+3 Design (Nmax=36) r’ 8.0 x 10° DL4 7 — 40x10° i DL3 cr’ 2.0.x 10° DL2 cr’ 1.0 x 106 DLI 0.3 x 108 => a DLS DL: Dose levels (CAR+ T cells/kg) DL7 16.0 x 10° DL6 12.0 x 10° DL6 skipped bosed on safety data R
Slide 5: Study Enrolled Heavily Treated Subjects with R/R SCLC or LCNEC
4 Study Enrolled Heavily Treated Subjects with R/R SCLC or LCNEC The study population comprised 20 subjects with relapsed and/or refractory (R/R) SCLC or LCNEC Most subjects had SCLC, with extensive-stage disease at initial diagnosis 70% of subjects had history of brain metastases 95% of subjects re
Slide 6: Safety was Manageable, No DLTs or LB2102-related Deaths
4 Safety was Manageable, No DLTs or LB2102-related Deaths DLland DL3 DL4 DLS DL7 Total DL2 (N=3) (N=3) (N=3) (N=5) (N=20) (N=6) Any TEAE 6 (100) 3 (100) 3 (100) 3 (100) 5 (100) 20 (100) — = i ie i a i he zs wi is a * CRS occurred in 6 subjects (30%) all Grade < 2 Any TRAE 5 (83.3) 1(33.3) 3(100) 2(6
Slide 7: CAR-T Cells Measurable; Subjects With PR had Higher PK Exposure
CAR copy number in blood (copies/jig gDNA) > 4 CAR-T Cells Were Measurable in Subjects With a PR had Higher PK Exposure All Subjects at > DL3 . . a) * PK analyses were conducted using peripheral Es blood samples from 20 subjects ® A . —ns + At DL 2 3 (2.0-16 x 10° CAR-T cells/kg) 3 ri] | T. o Median
Slide 8: At DL3 and Above, Objective Response Rate is 28.6%
Percent Change From Baseline 400 4 100 ~ 4 At DL3 and Above, the Objective Response Rate (ORR) is 28.6% Disease Control Rate (DCR) is 78.6% Best Responses (per RECIST 1.1) Primary tumor type ® scic & LONEC sO x. oe * 9 8 aE sD sp a i a me Bos. Subjects at ff Note: 2 subjects with progressing disease
Slide 9: Responses to LB2102 are Durable
Subjects LCNEC scic 4 Responses to LB2101 are Durable Days Since LB2102 Infusion a a ?° 2 = @ ———@® Duration of Response (DOR): 185 days * . co - . * 2 . . co x s 4. os a s “@ DOR: 208 days a a . e . s 2 . . DOR: 36+ days ite ne s . . s DOR: 31+ days ~~ i s Overall Response —s— ® Partial response (P
Slide 10: Durable PR in a Subject with Refractory SCLC
4 Durable PR in a Subject with Refractory SCLC Treated Off-protocol with LB2102 Before LB2102 Infusion Month 12 After Infusion One subject treated off- protocol at DL3 achieved durable PR (ongoing at 12 mo; data not included in this trial) Durable ~80% tumor reduction with symptom resolution and sus
Slide 11: Conclusions
4 Conclusions DLL3-targeted CAR-T LB2102 has a favorable safety profile: Phase 1 study (n=20) in patients with R/R SCLC and LCNEC demonstrated no DLTs, with manageable CRS and ICANS Encouraging anti-tumor activity: at DL > 3, ORR of 28.6% and a DCR of 78.6% Responses are durable: median DOR 6.5 mo w
Slide 12: Acknowledgements
FF Acknowledgements We thank all site staff, patients, families, and caregivers for their participation. Special thanks to the study investigators: Jacob Sands MD (Dana-Farber Cancer Institute, Boston, MA) Adam J. Schoenfeld MD (Memorial Sloan Kettering Cancer Center, New York City, NY) Alberto Chia